Correction to Evaluation of Liver Disease Progression in the German Hepatitis C Virus (1b)-Contaminated Anti-D Cohort at 35 Years After Infection [59 49-57] Doi: 10.1002/hep.26644;Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection

Hepatology

Volumn 59, Issue 1, 2014, Pages 49-57

  Wiese, Manfred ^a   Fischer, Janett ^b   Löbermann, Micha ^c   Göbel, Uwe ^d   Grüngreiff, Kurt ^e   Güthoff, Wolfgang ^f   Kullig, Ulrike ^g   Richter, Franziska ^a   Schiefke, Ingolf ^h   Tenckhoff, Hannelore ^b   Zipprich, Alexander ⁱ   Berg, Thomas ^b   Müller, Tobias ^b   Böhm, Stephan ^j   Ende, Katrin ^j   Herrmann, Andreas ^j   Herzig, Sabine ^j   Heuchel, Thomas ^j   Hönicke, Holm ^k   König, Ingrid ^l   Meyer Siegert, Edeltraud ^j   Oesen, Ute ^j   Schaffranke, Annette ^j   Stein, Kerstin ^j   Waizmann, Michael ^j   Walther, Tatjana ^j   Wiegand, Johannes ^j   Wollschläger, Sven ^j   Berr, Frieder ^j   Porst, Heiner ^j   Lafrenz, Michael ^j   more..

^a Hepatologische Schwerpunktpraxis   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^d Gastroenterologische Schwerpunkt Praxis   (Germany)

^e Hepatologische Schwerpunktpraxis im Bng   (Germany)

^f E v Bergmann Hospital   (Germany)

^g ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^h Klinikum St Georg   (Germany)

ⁱ MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^j NONE   (Germany)

^k NONE   (Germany)

^l NONE   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RHESUS D ANTIBODY; RIBAVIRIN; ALLOANTIBODY; ANTIVIRUS AGENT; RHO(D) ANTIBODY;

ADOLESCENT; ANTIVIRAL THERAPY; ARTICLE; DISEASE COURSE; END STAGE LIVER DISEASE; FEMALE; FOLLOW UP; GERMANY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1B; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; ADULT; AGED; DRUG CONTAMINATION; IATROGENIC DISEASE; MIDDLE AGED; MULTICENTER STUDY; SURVIVAL; YOUNG ADULT; CLINICAL TRIAL;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DRUG CONTAMINATION; FEMALE; FOLLOW-UP STUDIES; GERMANY; HEPATITIS C; HUMANS; IATROGENIC DISEASE; ISOANTIBODIES; LIVER CIRRHOSIS; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84894880765     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27684     Document Type: Erratum

References (24)

1. Global Burden Of Hepatitis CWG. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004;44:20-29.
2. European Association for the Study of the L. EASL Clinical Practice Guidelines:management of hepatitis C virus infection. J Hepatol 2011;55:245-264.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Disease. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374.
4. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann InternMed 2012;156:271-278.
5. Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Muhlberger N, et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology 2012;143:974-985 e914.
6. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012;206:469-477.
7. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progressionrates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008;48:418-431.
8. Seeff LB. Natural history of hepatitis C. Hepatology 1997;26:21S-28S.
9. Barrett S, Goh J, Coughlan B, Ryan E, Stewart S, Cockram A, et al. Thenatural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut 2001;49:423-430.
10. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-1233.
11. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. Hepatology 2000;32:91-96.
12. Wiese M, Grungreiff K, Guthoff W, Lafrenz M, Oesen U, Porst H; East GermanHepatitis CSG. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany-a 25-year multicenter study. J Hepatol 2005;43:590-598.
13. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
14. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801.
15. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology 2005;42:5-13.
16. Tillmann HL, Wiese M, Braun Y, Wiegand J, Tenckhoff S, Mossner J, et al. Quality of life in patients with various liver diseases: patients with HCV show greater mental impairment, while patients with PBC have greater physical impairment. J Viral Hepat 2011;18:252-261.
17. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008;134:1699-1714.
18. Alter HJ. HCV natural history: the retrospective and prospective in perspective. J Hepatol 2005;43:550-552.
19. Ferenci P, Ferenci S, Datz C, Rezman I, Oberaigner W, Strauss R. Morbidity and mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation inthe 1970s. J Hepatol 2007;47:31-36.
20. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
21. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
22. Gordon SC, Elloway RS, Long JC, Dmuchowski CF. The pathology of hepatitis C as afunction of mode of transmission: blood transfusion vs. intravenous drug use. Hepatology 1993;18:1338-1343.
23. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513-521, 521.e1-6.
24. Levine RA, Sanderson SO, Ploutz-Snyder R, Murray F, Kay E, Hegarty J, et al. Assessment of fibrosis progression in untreated Irish women with chronic hepatitis C contracted from immunoglobulin anti-D. Clin Gastroenterol Hepatol 2006;4:1271-1277.